Mirati Therapeutics sold by Avoro Capital Advsiors LLC $6.36m in shares-July 23

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company.

The Company is focused on developing a pipeline of targeted oncology products.

The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat.

MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors.

Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors.

MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development.

Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development.

Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL),

specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

Number of employees : 51 people.